Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 39 results.
User Information
Export Records
  1. 1.   Distinct allosteric networks in CDK4 and CDK6 in the cell cycle and in drug resistance
  2. Zhang,Wengang; Bradburn, Devin; Heidebrink, Gretchen; Liu, Yonglan; Jang,Hyunbum; Nussinov,Ruth; Kõivomägi, Mardo
  3. Journal of Molecular Biology. 2025, Mar 31; 169121.
  1. 2.   Slower CDK4 and faster CDK2 activation in the cell cycle
  2. Zhang,Wengang; Liu,Yonglan; Jang,Hyunbum; Nussinov,Ruth
  3. Structure (London, England : 1993). 2024, Apr 23;
  1. 3.   Plant Natural Products in Anticancer Drug Discovery
  2. Grothaus, P. G.; Cragg, G. M.; Newman, D. J.
  3. Current Organic Chemistry. 2010, Oct; 14(16): 1781-1791.
  1. 4.   A dual role of Cdk2 in DNA damage response
  2. Satyanarayana, A.; Kaldis, P.
  3. Cell Division. 2009, May; 4: 4.
  1. 5.   Rb/Cdk2/Cdk4 triple mutant mice elicit an alternative mechanism for regulation of the G(1)/S transition
  2. Li, W.; Kotoshiba, S.; Berthet, C.; Hilton, M. B.; Kaldis, P.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2009 106(2): 486-491.
  1. 6.   Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo
  2. Suh, H. C.; Leeanansaksiri, W.; Ji, M.; Klarmann, K. D.; Renn, K.; Gooya, J.; Smith, D.; McNiece, I.; Lugthart, S.; Valk, P. J.; Delwel, R.; Keller, J. R.
  3. Oncogene. 2008, Sep 18; 27(42): 5612-5623.
  1. 7.   Genetic substitution of Cdk1 by Cdk2 leads to embryonic lethality and loss of meiotic function of Cdk2
  2. Satyanarayana, A.; Berthet, C.; Lopez-Molina, J.; Coppola, V.; Tessarollo, L.; Kaldis, P.
  3. Development. 2008 135(20): 3389-3400.
  1. 8.   p21 inhibits Cdk1 in the absence of Cdk2 to maintain the G1/S phase DNA damage checkpoint
  2. Satyanarayana, A.; Hilton, M. B.; Kaldis, P.
  3. Molecular Biology of the Cell. 2008 19(1): 65-77.
  1. 9.   Cell-specific responses to loss of cyclin-dependent kinases
  2. Berthet, C.; Kaldis, P.
  3. Oncogene. 2007, Jul; 26(31): 4469-4477.
  1. 10.   Natural products from marine invertebrates and microbes as modulators of antitumor targets
  2. Newman, D. J.; Cragg, G. M.
  3. Current Drug Targets. 2006, MAR; 7(3): 279-304.
  1. 11.   Cell cycle sibling rivalry - Cdc2 vs. Cdk2
  2. Kaldis, P.; Aleem, E.
  3. Cell Cycle. 2005, NOV; 4(11): 1491-1494.
  1. 12.   Cytokine-driven cell cycling is mediated through Cdc25A
  2. Khaled, A. R.; Bulavin, D. V.; Kittipatarin, C.; Li, W. Q.; Alvarez, M.; Kim, K.; Young, H. A.; Fornace, A. J.; Durum, S. K.
  3. Journal of Cell Biology. 2005, JUN 6; 169(5): 755-763.
  1. 13.   Homology model of the CDK1/cyclin B complex
  2. McGrath, C. F.; Pattabiraman, N.; Kellogg, G. E.; Lemcke, T.; Kunick, C.; Sausville, E. A.; Zaharevitz, D. W.; Gussio, R.
  3. Journal of Biomolecular Structure & Dynamics. 2005, APR; 22(5): 493-502.
  1. 14.   The N-terminal peptide of the Kaposi's sarcoma-associated herpesvirus (KSHV)-cyclin determines substrate specificity
  2. Kaldis, P.
  3. Journal of Biological Chemistry. 2005, MAR 25; 280(12): 11165-11174.
  1. 15.   The search for novel drug leads for predominately antitumor therapies by utilizing mother nature's pharmacophoric libraries
  2. Kingston, D. G. I.; Newman, D. J.
  3. Current Opinion in Drug Discovery & Development. 2005, MAR; 8(2): 207-227.
  1. 16.   Effect of cell cycle inhibition on cisplatin-induced cytotoxicity
  2. Fishel, M. L.; Newell, D. R.; Griffin, R. J.; Davison, R.; Wang, L. Z.; Curtin, N. J.; Zuhowski, E. G.; Kasza, K.; Egorin, M. J.; Moschel, R. C.; Dolan, M. E.
  3. Journal of Pharmacology and Experimental Therapeutics. 2005, JAN; 312(1): 206-213.
  1. 17.   Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation
  2. Vazquez, N.; Greenwell-Wild, T.; Marinos, N. J.; Swaim, W. D.; Nares, S.; Ott, D. E.; Schubert, U.; Henklein, P.; Orenstein, J. M.; Sporn, M. B.; Wahl, S. M.
  3. Journal of Virology. 2005 79(7): 4479-4491.
  1. 18.   Induction of apoptosis by flavopiridol in human neuroblastoma cells is enhanced under hypoxia and associated with N-myc proto-oncogene down-regulation
  2. Puppo, M.; Pastorino, S.; Melillo, G.; Pezzolo, A.; Varesio, L.; Bosco, M. C.
  3. Clinical Cancer Research. 2004, DEC 15; 10(24): 8704-8719.
  1. 19.   Inhibition of melanoma growth and metastasis by ATF2-derived peptides
  2. Bhoumik, A.; Gangi, L.; Ronai, Z.
  3. Cancer Research. 2004, NOV 15; 64(22): 8222-8230.
  1. 20.   Tuberous sclerosis complex 2 gene product interacts with human SMAD proteins - A molecular link of two tumor suppressor pathways
  2. Birchenall-Roberts, M. C.; Fu, T.; Bang, O. S.; Dambach, M.; Resau, J. H.; Sadowski, C. L.; Bertolette, D. C.; Lee, H. J.; Kim, S. J.; Ruscetti, F. W.
  3. Journal of Biological Chemistry. 2004 279(24): 25605-25613.
  1. 21.   Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data
  2. Wallqvist, A.; Rabow, A. A.; Shoemaker, R. H.; Sausville, E. A.; Covell, D. G.
  3. Bioinformatics. 2003 19(17): 2212-2224.
  1. 22.   Cdk2 knockout mice are viable
  2. Berthet, C.; Aleem, E.; Coppola, V.; Tessarollo, L.; Kaldis, P.
  3. Current Biology. 2003 13(20): 1775-1785.
  1. 23.   Plants as a source of anti-cancer and anti-HIV agents
  2. Cragg, G. M.; Newman, D. J.
  3. Annals of Applied Biology. 2003 143(2): 127-133.
  1. 24.   Rarity of CDK4 germline mutations in familial melanoma
  2. Goldstein, A. M.; Chidambaram, A.; Halpern, A.; Holly, E. A.; Guerry, D.; Sagebiel, R.; Elder, D. E.; Tucker, M. A.
  3. Melanoma Research. 2002 12(1): 51-55.
  1. 25.   CAK1 promotes meiosis and spore formation in Saccharomyces cerevisiae in a CDC28-independent fashion
  2. Schaber, M.; Lindgren, A.; Schindler, K.; Bungard, D.; Kaldis, P.; Winter, E.
  3. Molecular and Cellular Biology. 2002 22(1): 57-68.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel